CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells

European Journal of Immunology

Volumn 40, Issue 1, 2010, Pages 124-133

  Overstreet, Michael G ^a,b   Freyberger, Helen ^a   Cockburn, Ian A ^a   Chen, Yun Chi ^a   Tse, Sze Wah ^a   Zavala, Fidel ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

B cell; CpG; PD 1; Peptide; T cell

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; SERYLTYROSYLVALYLPROLYLSERYLALANYLGLUTAMYLGLUTAMINYLISOLEUCINE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; PEPTIDE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL SURFACE; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CPG ISLAND; CYTOLOGY; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CPG ISLANDS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PEPTIDES;

EID: 74249083537     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939493     Document Type: Article

References (44)

1. + T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infect. Immun. 2008. 76: 3628-3631.
2. + T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 2007. 13: 1035-1041.
3. + T cell clones correlates with their levels of expression of adhesion molecules. J. Exp. Med. 1992. 175: 895-905.
4. + cytolytic T-cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 1991. 3: 579-585.
5. Sano, G., Hafalla, J. C., Morrot, A., Abe, R., Lafaille, J. J. and Zavala, F., Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J. Exp. Med. 2001. 194: 173-180.
6. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H. and Pircher, H., T cell priming versus T-cell tolerance induced by synthetic peptides. J. Exp. Med. 1995. 182: 261-266.
7. Kyburz, D., Aichele, P., Speiser, D. E., Hengartner, H., Zinkernagel, R. M. and Pircher, H., T cell immunity after a viral infection versus T-cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 1993. 23: 1956-1962.
8. Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M. and Melief, C. J., Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 1996. 156: 3911-3918.
9. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J. and Kast, W. M., Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 1996. 93: 7855-7860.
10. Bijker, M. S., van den Eeden, S. J., Franken, K. L., Melief, C. J., van der Burg, S. H. and Offringa, R., Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 2008. 38: 1033-1042.
11. + CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 2007. 179: 5033-5040.
12. Valmori, D., Romero, J. F., Men, Y., Maryanski, J. L., Romero, P. and Corradin, G., Induction of a cytotoxic T-cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur. J. Immunol. 1994. 24: 1458-1462.
13. Widmann, C., Romero, P., Maryanski, J. L., Corradin, G. and Valmori, D., T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods 1992. 155: 95-99.
14. Ahonen, C. L., Doxsee, C. L., McGurran, S. M., Riter, T. R., Wade, W. F., Barth, R. J., Vasilakos, J. P. et al., Combined TLR and CD40 triggering induces potent CD81 T-cell expansion with variable dependence on type I IFN. J. Exp. Med. 2004. 199: 775-784.
15. Assudani, D., Cho, H. I., Devito, N., Bradley, N. and Celis, E., In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res. 2008. 68: 9892-9899.
16. + T-cell responses. J. Immunol. 2006. 177: 8860-8873.
17. + T-cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin. Immunol. 2007. 124: 119-130.
18. + T-cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 2005. 331: 151-158.
19. Toubaji, A., Hill, S., Terabe, M., Qian, J., Floyd, T., Simpson, R. M., Berzofsky, J. A. and Khleif, S. N., The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007. 25: 5882-5891.
20. Iwasaki, A. and Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. 5: 987-995.
21. Krieg, A. M., CpG motifs in bacterial DNA and their immune effects. Annu Rev. Immunol. 2002. 20: 709-760.
22. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J. and Ahmed, R., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006. 439: 682-687.
23. Minami, Y., Kono, T., Miyazaki, T. and Taniguchi, T., The IL-2 receptor complex: its structure, function, and target genes. Annu. Rev. Immunol. 1993. 11: 245-268.
24. Bennett, S. R., Carbone, F. R., Toy, T., Miller, J. F. and Heath, W. R., B cells directly tolerize CD8(+) T cells. J. Exp. Med. 1998. 188: 1977-1983.
25. Fuchs, E. J. and Matzinger, P., B cells turn off virgin but not memory T cells. Science 1992. 258: 1156-1159.
26. Tian, J., Zekzer, D., Hanssen, L., Lu, Y., Olcott, A. and Kaufman, D. L., Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 2001. 167: 1081-1089.
27. Watt, V., Ronchese, F. and Ritchie, D., Resting B cells suppress tumor immunity via an MHC class-II-dependent mechanism. J. Immunother. 2007. 30: 323-332.
28. Werner-Klein, M., Dresch, C., Marconi, P. and Brocker, T., Transcriptional targeting of B cells for induction of peripheral CD8 T cell tolerance. J. Immunol. 2007. 178: 7738.
29. Sharpe, A. H., Wherry, E. J., Ahmed, R. and Freeman, G. J., The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 2007. 8: 239-245.
30. Tsushima, F., Yao, S., Shin, T., Flies, A., Flies, S., Xu, H., Tamada, K. et al., Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007. 110: 180-185.
31. Lanzavecchia, A., Antigen-specific interaction between T and B cells. Nature 1985. 314: 537-539.
32. Gray, D., Gray, M. and Barr, T., Innate responses of B cells. Eur. J. Immunol. 2007. 37: 3304-3310.
33. Lipford, G. B., Sparwasser, T., Zimmermann, S., Heeg, K. and Wagner, H., CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol. 2000. 165: 1228-1235.
34. Yi, A. K., Chang, M., Peckham, D. W., Krieg, A. M. and Ashman, R. F., CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 1998. 160: 5898-5906.
35. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A. and Klinman, D. M., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995. 374: 546-549.
36. Heit, A., Huster, K. M., Schmitz, F., Schiemann, M., Busch, D. H. and Wagner, H., CpG-DNA aided cross-priming by cross-presenting B cells. J. Immunol. 2004. 172: 1501.
37. Barr, T. A., Brown, S., Ryan, G., Zhao, J. and Gray, D., TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. Eur. J. Immunol. 2007. 37: 3040-3053.
38. Lenert, P., Brummel, R., Field, E. H. and Ashman, R. F., TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 2005. 25: 29-40.
39. + T cells: role of TGF-beta 1. J. Immunol. 2003. 170: 5897-5911.
40. + phenotype controls T-cell-dependent inflammatory responses. Immunity 2008. 28: 639-650.
41. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z. K., Ballas, Z. K. and Endres, S. et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol 2001. 31: 2154-2163.
42. Kerkmann, M., Rothenfusser, S., Hornung, V., Towarowski, A., Wagner, M., Sarris, A. Giese, T., et al., Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol 2003. 170: 4465-4474.
43. Fillatreau, S., Gray, D. and Anderton, S. M., Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 2008. 8: 391-397.
44. Carvalho, L. H., Hafalla, J. C. and Zavala, F., ELISPOT assay to measure antigen-specific murine CD8(1) T-cell responses. J. Immunol. Methods 2001. 252: 207-218.